1. Sá, KN, Moreira, L, Baptista, AF, et al Prevalence of chronic pain in developing countries: systematic review and meta-analysis. Pain Rep 2019; 4: e779.
Google Scholar | Crossref | Medline2. McWilliams, DF, Walsh, DA. Pain mechanisms in rheumatoid arthritis. Clin Exp Rheumatol 2017; 35 Suppl 107: 94–101.
Google Scholar3. Alles, SRA, Smith, PA. Etiology and pharmacology of neuropathic pain. Pharmacol Rev 2018; 70: 315–347.
Google Scholar | Crossref | Medline4. IASP Taxonomy . (2011). International Association for the study of pain. IASP Publications, http://www.iasp-pain.org/Taxonomy-Neuropathicpain (, accessed 16 January 2015).
Google Scholar5. Colloca, L, Ludman, T, Bouhassira, D, et al Neuropathic pain. Nat Rev Dis Primers 2017; 3: 17002. Published 2017 Feb 16.
Google Scholar | Crossref | Medline6. Yalcin, I, Barthas, F, Barrot, M. Emotional consequences of neuropathic pain: insight from preclinical studies. Neurosci Biobehav Rev 2014; 47: 154–164.
Google Scholar | Crossref | Medline7. Torta, R, Ieraci, V, Zizzi, F. A review of the emotional aspects of neuropathic pain: from comorbidity to co-pathogenesis. Pain Ther 2017; 6: 11–17.
Google Scholar | Crossref | Medline8. Nicholson, B, Verma, S. Comorbidities in chronic neuropathic pain. Pain Med 2004; 5: S9–S27.
Google Scholar | Crossref | Medline9. Radat, F, Margot-Duclot, A, Attal, N. Psychiatric co-morbidities in patients with chronic peripheral neuropathic pain: a multicentre cohort study. Eur J Pain 2013; 17: 1547–1557.
Google Scholar | Medline10. Humo, M, Lu, H, Yalcin, I. The molecular neurobiology of chronic pain-induced depression. Cell Tissue Res 2019; 377: 21–43.
Google Scholar | Crossref | Medline11. Finnerup, NB, Attal, N, Haroutounian, S, et al Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 2015; 14: 162–173.
Google Scholar | Crossref | Medline | ISI12. Attal, N, Cruccu, G, Baron, R, et al EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010; 17: 1113–e88.
Google Scholar | Crossref13. Więdłocha, M, Marcinowicz, P, Krupa, R, et al Effect of antidepressant treatment on peripheral inflammation markers: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2018; 80: 217–226.
Google Scholar | Crossref | Medline14. Wattiez, AS, Dupuis, A, Privat, AM, et al Disruption of 5-HT 2A -PDZ protein interaction differently affects the analgesic efficacy of SSRI, SNRI and TCA in the treatment of traumatic neuropathic pain in rats. Neuropharmacol 2017; 125: 308–318.
Google Scholar | Crossref | Medline15. Dupuis, A, Wattiez, AS, Pinguet, J, et al Increasing spinal 5-HT 2A receptor responsiveness mediates anti-allodynic effect and potentiates fluoxetine efficacy in neuropathic rats. Evidence for GABA release. Pharmacol Res 2017; 118: 93–103.
Google Scholar | Crossref | Medline16. Sindrup, SH, Gram, LF, Brøsen, K, et al The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 1990; 42: 135–144.
Google Scholar | Crossref | Medline | ISI17. Giannopoulos, S, Kosmidou, M, Sarmas, I, et al Patient compliance with SSRIs and gabapentin in painful diabetic neuropathy. Clin J Pain 2007; 23: 267–269.
Google Scholar | Crossref | Medline18. Wang, SM, Han, C, Bahk, WM, et al Addressing the side effects of contemporary antidepressant drugs: a comprehensive review. Chonnam Med J 2018; 54: 101–112.
Google Scholar | Crossref | Medline19. Urits, I, Peck, J, Orhurhu, MS, et al Off-label antidepressant use for treatment and management of chronic pain: evolving understanding and comprehensive review. Curr Pain Headache Rep 2019; 23: 66.
Google Scholar | Crossref | Medline20. Food and Drug Administration . BrintellixTM (vortioxetine) tablets for oral use. Full prescribing information, http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204447s000lbl.pdf (2013, accessed 13 February 2021).
Google Scholar21. European Medicines Agency . EPAR brintellix product information. Annex I. Summary of product characteristics, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Product_Information/human/002717/WC500159449.pdf (2014, accessed 13 Feruary 2021).
Google Scholar22. WHO Collaborating Centre for Drug Statistics Methodology . Oslo: ATC classification index with DDDs, https://www.whocc.no/atc/
Google Scholar23. Micov, AM, Tomić, MA, Todorović, MB, et al Vortioxetine reduces pain hypersensitivity and associated depression-like behavior in mice with oxaliplatin-induced neuropathy. Prog Neuropsychopharmacol Biol Psychiatry 2020; 103: 109975.
Google Scholar | Crossref | Medline24. Salagre, E, Grande, I, Solé, B, et al Vortioxetine: a new alternative for the treatment of major depressive disorder. Rev Psiquiatr Salud Ment 2018; 11: 48–59.
Google Scholar | Crossref | Medline25. Sowa-Kućma, M, Pańczyszyn-Trzewik, P, Misztak, P, et al Vortioxetine: a review of the pharmacology and clinical profile of the novel antidepressant. Pharmacol Rep 2017; 69: 595–601.
Google Scholar | Crossref | Medline26. Sanchez, C, Asin, KE, Artigas, F. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther 2015; 145: 43–57.
Google Scholar | Crossref | Medline | ISI27. Riga, MS, Sánchez, C, Celada, P, et al Involvement of 5-HT 3 receptors in the action of vortioxetine in rat brain: focus on glutamatergic and GABAergic neurotransmission. Neuropharmacol 2016; 108: 73–81.
Google Scholar | Crossref | Medline | ISI28. Frampton, JE . Vortioxetine: a review in cognitive dysfunction in depression. Drugs 2016; 76: 1675–1682.
Google Scholar | Crossref | Medline29. Gonda, X, Sharma, SR, Tarazi, FI. Vortioxetine: a novel antidepressant for the treatment of major depressive disorder. Expert Opin Drug Discov 2019; 14: 81–89.
Google Scholar | Crossref | Medline30. Pehrson, AL, Hillhouse, TM, Haddjeri, N, et al Task- and treatment length-dependent effects of vortioxetine on scopolamine-induced cognitive dysfunction and Hippocampal extracellular acetylcholine in rats. J Pharmacol Exp Ther 2016; 358: 472–482.
Google Scholar | Crossref | Medline31. Mørk, A, Pehrson, A, Brennum, LT, et al Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther 2012; 340: 666–675.
Google Scholar | Crossref | Medline | ISI32. Lecours, M, El Mansari, M, Blier, P. P.2.b.015 electrophysiological effects of the multimodal antidepressant Lu AA21004 on serotonin transmission in the rat hippocampus. Eur Neuropsychopharmacol 2012; 22: S249.
Google Scholar | Crossref33. Bonaventure, P, Dugovic, C, Kramer, M, et al Translational evaluation of JNJ-18038683, a 5-hydroxytryptamine type 7 receptor antagonist, on rapid eye movement sleep and in major depressive disorder. J Pharmacol Exp Ther 2012; 342: 429–440.
Google Scholar | Crossref | Medline34. Stenkrona, P, Halldin, C, Lundberg, J. 5-HTT and 5-HT1A receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects. Eur Neuropsychopharmacol 2013; 23: 1190–1198.
Google Scholar | Crossref | Medline35. Vahid-Ansari, F, Zhang, M, Zahrai, A, et al Overcoming resistance to selective serotonin reuptake inhibitors: targeting serotonin, serotonin-1A receptors and adult neuroplasticity. Front Neurosci 2019; 13: 404.
Google Scholar | Crossref | Medline36. Okada, M, Okubo, R, Fukuyama, K. Vortioxetine subchronically activates serotonergic transmission via desensitization of Serotonin 5-HT1A receptor with 5-HT3 receptor inhibition in rats. Int J Mol Sci 2019; 20: 6235.
Google Scholar | Crossref37. El Mansari, M, Lecours, M, Blier, P. Effects of acute and sustained administration of vortioxetine on the serotonin system in the hippocampus: electrophysiological studies in the rat brain. Psychopharmacology (Berl) 2015; 232: 2343–2352.
Google Scholar | Crossref | Medline | ISI38. Okubo, R, Hasegawa, T, Fukuyama, K, et al Current limitations and candidate potential of 5-HT7 receptor antagonism in psychiatric pharmacotherapy. Front Psychiatry 2021; 12: 623684.
Google Scholar | Crossref | Medline39. du Jardin, KG, Jensen, JB, Sanchez, C, et al Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: a potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism. Eur Neuropsychopharmacol 2014; 24: 160–171.
Google Scholar | Crossref | Medline40. Jensen, JB, du Jardin, KG, Song, D, et al Vortioxetine, but not escitalopram or duloxetine, reverses memory impairment induced by central 5-HT depletion in rats: evidence for direct 5-HT receptor modulation. Eur Neuropsychopharmacol 2014; 24: 148–159.
Google Scholar | Crossref | Medline41. Wallace, A, Pehrson, AL, Sánchez, C, et al Vortioxetine restores reversal learning impaired by 5-HT depletion or chronic intermittent cold stress in rats. Int J Neuropsychopharmacol 2014; 17: 1695–1706.
Google Scholar | Crossref | Medline | ISI42. Jiang, LX, Huang, GD, Su, F, et al Vortioxetine administration attenuates cognitive and synaptic deficits in 5×FAD mice. Psychopharmacology (Berl) 2020; 237: 1233–1243.
Google Scholar | Crossref | Medline43. McIntyre, RS, Lophaven, S, Olsen, CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol 2014; 17: 1557–1567.
Google Scholar | Crossref | Medline | ISI44. Mahableshwarkar, AR, Jacobsen, PL, Chen, Y, et al A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. Psychopharmacology (Berl) 2015; 232: 2061–2070.
Google Scholar | Crossref | Medline | ISI45. McIntyre, RS, Harrison, J, Loft, H, et al The effects of vortioxetine on cognitive function in patients with major depressive disorder: a meta-analysis of three randomized controlled trials. Int J Neuropsychopharmacol 2016; 19: w055.
Google Scholar | Crossref46. McIntyre, RS, Florea, I, Tonnoir, B, et al Efficacy of vortioxetine on cognitive functioning in working patients with major depressive disorder. J Clin Psychiatry 2017; 78: 115–121.
Google Scholar | Crossref | Medline47. Baune, BT, Brignone, M, Larsen, KG. A network meta-analysis comparing effects of various antidepressant classes on the digit symbol substitution test (DSST) as a measure of cognitive dysfunction in patients with major depressive disorder. Int J Neuropsychopharmacol 2018; 21: 97–107.
Google Scholar | Crossref | Medline48. Vieta, E, Sluth, LB, Olsen, CK. The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: a short-term, randomized, double-blind, exploratory study versus escitalopram. J Affect Disord 2018; 227: 803–809.
Google Scholar | Crossref | Medline49. Freeman, MP, Cheng, LJ, Moustafa, D, et al Vortioxetine for major depressive disorder, vasomotor, and cognitive symptoms associated with the menopausal transition. Ann Clin Psychiatry 2017; 29: 249–257.
Google Scholar | Medline50. Smith, J, Browning, M, Conen, S, et al Vortioxetine reduces BOLD signal during performance of the N-back working memory task: a randomised neuroimaging trial in remitted depressed patients and healthy controls. Mol Psychiatry 2018; 23: 1127–1133.